Meeting
2022 ASCO Quality Care Symposium
Health care costs among men with metastatic castration-resistant prostate cancer (mCRPC) in the U.S. Medicare population.
Authors
Stephen J. Freedland
Division of Urology, Department of Surgery, Cedars-Sinai Medical Center and Department of Surgery, Durham Veterans Affairs Health Care System, Durham, NC
Stephen J. Freedland, Matthew Davis, Andrew J. Epstein, Bhakti Arondekar, Jasmina I. Ivanova
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Cost, Value, and Policy,Health Care Access, Equity, and Disparities,Patient Experience
Sub Track
Cost and Cost-Effectiveness of Care
Citation
J Clin Oncol 40, 2022 (suppl 28; abstr 10)
DOI
10.1200/JCO.2022.40.28_suppl.010
Abstract #
10
Poster Bd #
A8
Abstract Disclosures
Similar Posters
Poster
2016 Genitourinary Cancers Symposium
Docetaxel chemotherapy in metastatic castration-resistant prostate cancer (mCRPC): Cost of care for Medicare and commercially insured men.
First Author: Andrew J. Armstrong
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world treatment patterns in patients with BRCA 1/2-positive (BRCA+) metastatic castration-resistant prostate cancer (mCRPC) initiating first-line (1L) therapy.
First Author: Mehmet Asim Bilen
Poster
2023 ASCO Genitourinary Cancers Symposium
Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study.
First Author: Vincenzo Gennusa
Poster
2023 ASCO Genitourinary Cancers Symposium
Radium-223 for mCRPC, a real-world experience study from 7 Galician medical centers.
First Author: Urbano Anido Herranz